Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain

• DOI: 10.1111/pai.13942
• Publication Date: 2023-04-08T08:30:00Z
• Authors: María Nieto‐Cid; Teresa Garriga‐Ba...; Ana Mª. Plaza‐Martín; Miguel Tortajada‐...; Javier Torres‐Bor...; Jaime Lozano‐Blasco; Laura Moreno‐Gala...; Mª. del Mar Folqu...; Montse Bosque‐García; Mirella Gaboli; Alejandro López‐N...; Cristina Rivas‐Ju...; Mª. Araceli Cabal...; Andrea Freixa‐Ben...; Laura Valdesoiro‐...; Inés de Mir‐Messa; Esther Ballester‐...; María Penín‐Antón; Raquel Romero‐García; Juan Navarro‐Morón; Alfredo Valenzuel...; Mercedes Sánchez‐...; José Batlles‐Garrido; Verónica Sanz‐San...; Álvaro Gimeno‐Día...; Anselmo Andrés‐Ma...; Elena Campos‐Alonso; David Gómez‐Pastrana; Elena Vázquez‐Rod...; Luz Martínez‐Pardo; Genoveva del Río‐...; Ángel Mazón‐Ramos; Antonio Nieto‐García
• Keywords: Omalizumab; Allergic asthma

Abstract Background Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use omalizumab for the treatment these patients has produced significant improvement several clinical outcomes, but at same time, cost management disease also increased. aim this report was to evaluate whether is cost‐effective. Methods A sample 426 children with SPAA from ANCHORS (Asthma iN CHildren: Omalizumab Real‐life Spain) study used calculate incremental cost‐effectiveness ratio (ICER) avoidance moderate‐to‐severe exacerbations (MSE) childhood Asthma Control Test (c‐ACT) or Questionnaire (ACQ5). We retrospectively collected data on health encounters drug consumption before up 6 years after beginning omalizumab. Results ICER per avoided MSE €2107 1 year, it consistently decreased €656 those followed years. Similarly, minimally important difference control tests showed decrease €2059 €380 each 0.5 points ACQ5 €3141 €2322 3 c‐ACT, 6, respectively. Conclusion OMZ cost‐effective option most uncontrolled SPAA, especially who have frequent exacerbations; costs are progressively reduced successive treatment.